Gwendolyn Wu is a reporter at BioPharma Dive. She focuses on biotech startups, venture capital, and the healthcare ecosystem, with a particular emphasis on pharmaceuticals and medical specialties. Gwendolyn's work has been featured in notable publications including the Houston Chronicle, San Francisco Chronicle, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Gwendolyn Wu's coverage primarily revolves around the biotechnology industry, particularly focusing on press releases and private sector announcements. She is likely to be interested in pitches related to groundbreaking developments in biotech, such as new drug approvals, IPO filings, or significant funding rounds.
Given her focus on business (16%) within the context of biotechnology (45%), she may also be receptive to news about mergers and acquisitions involving biotech companies or innovative business strategies within the industry.
As Gwendolyn does not have a specific geographic focus mentioned, it is likely that she covers global developments in the field of biotechnology. Therefore, international perspectives and stories with broad relevance are more likely to resonate with her reporting interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
By: Gwendolyn Wu
The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.
By: Gwendolyn Wu
This story was originally published on BioPharma Dive . To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that's now resulted in 12 drug startups securing more than $4.1 billion combined.
The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.
Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.
The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.
